Results
The model showed that FeNO-SC, was associated with lower total cost than
SC (US $1333 vs. US $1452 average cost per patient), and higher QALYs
(0.93 vs 0.92 average per patient); showing dominance. A position of
dominance negates the need to calculate an incremental
cost-effectiveness ratio (Table 2 ).